Percutaneous left atrial appendage closure is not ready for routine clinical use

Published:October 10, 2017DOI:
      In this review, we challenge the use of left atrial appendage (LAA) occlusion with Watchman for stroke prevention in patients with atrial fibrillation on the basis of 1) unreliable and divergent results of the regulatory trials; 2) a strong inferiority signal from the Prospective Randomized Evaluation of the Watchman LAA Closure Device In Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy (PREVAIL) trial; 3) an uncertain pathophysiological basis for LAA occlusion; and 4) insufficient data to support Watchman in patients ineligible for anticoagulation.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • et al.
        • RE-LY Steering Committee and Investigators
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Patel M.R.
        • Mahaffey K.W.
        • Garg J.
        • et al.
        • ROCKET AF Investigators
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Granger C.B.
        • Alexander J.H.
        • McMurray J.J.V.
        • et al.
        ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Giugliano R.P.
        • Ruff C.T.
        • Braunwald E.
        • et al.
        • ENGAGE AF-TIMI 48 Investigators
        Edoxaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2013; 369: 2093-2104
        • Holmes D.R.
        • Reddy V.Y.
        • Turi Z.G.
        • Doshi S.K.
        • Sievert H.
        • Buchbinder M.
        • Mullin C.M.
        • Sick P.
        • PROTECT-AF Investigators
        Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.
        Lancet. 2009; 374 ([published correction appears in Lancet 2009;374(9701):1596]): 534-542
        • Holmes Jr., D.R.
        • Kar S.
        • Price M.J.
        • Whisenant B.
        • Sievert H.
        • Doshi S.K.
        • Huber K.
        • Reddy V.Y.
        Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
        J Am Coll Cardiol. 2014; 64: 1-12
      1. FDA Executive Summary P130013 Prepared for the October 8, 2014 meeting of the Circulatory System Devices Panel. Available at: Accessed November 10, 2017.

        • Holmes J.D.R.
        • Doshi S.K.
        • Kar S.
        • Price M.J.
        • Sanchez J.M.
        • Sievert H.
        • Valderrabano M.
        • Reddy V.Y.
        Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis.
        J Am Coll Cardiol. 2015; 65: 2614-2623
        • Kamel H.
        • Okin P.M.
        • Elkind M.S.V.
        • Iadecola C.
        Atrial fibrillation and mechanisms of stroke: time for a new model.
        Stroke. 2016; 47: 895-900
        • Zhou X.
        • Cao K.
        • Kou S.
        • Qu S.
        • Li H.
        • Yu Y.
        • Wang C.
        • Liu Y.
        • Li P.
        • Li D.
        Usefulness of CHADS2 score for prognostic stratification of patients with coronary artery disease: a systematic review and meta-analysis of cohort studies.
        Int J Cardiol. 2017; 228: 906-911
        • Mahajan R.
        • Brooks A.G.
        • Sullivan T.
        • Lim H.S.
        • Alasady M.
        • Abed H.S.
        • Ganesan A.N.
        • Nayyar S.
        • Lau D.H.
        • Roberts-Thomson K.C.
        • Kalman J.M.
        • Sanders P.
        Importance of the underlying substrate in determining thrombus location in atrial fibrillation: implications for left atrial appendage closure.
        Heart. 2012; 98: 1120-1126
        • Findlay M.D.
        • Thomson P.C.
        • Fulton R.L.
        • Solbu M.D.
        • Jardine A.G.
        • Patel R.K.
        • Stevens K.K.
        • Geddes C.C.
        • Dawson J.
        • Mark P.B.
        Risk factors of ischemic stroke and subsequent outcome in patients receiving hemodialysis.
        Stroke. 2015; 46: 2477-2481
        • Mant J.
        • Hobbs F.D.R.
        • Fletcher K.
        • Roalfe A.
        • Fitzmaurice D.
        • Lip G.Y.H.
        • Murray E.
        Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (BAFTA): a randomised controlled trial.
        Lancet. 2007; 370: 493-503
        • Connolly S.J.
        • Eikelboom J.
        • Joyner C.
        • et al.
        AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation.
        N Engl J Med. 2011; 364: 806-817